利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

171 条记录 (耗时 0.026 秒)

    HUMAN ENDOGENOUS RETROVIRAL PROTEIN
    6.
    发明申请
    HUMAN ENDOGENOUS RETROVIRAL PROTEIN 审中-公开

    公开(公告)号：WO2018234576A1

    公开(公告)日：2018-12-27

    申请号：PCT/EP2018/066837

    申请日：2018-06-22

    申请人： INSTITUT GUSTAVE ROUSSY

    发明人： HEIDMANN, Odile ,  HEIDMANN, Thierry

    IPC分类号： A61K39/00 ,  C07K14/005 ,  C07K16/30 ,  G01N33/574

    摘要： The application relates to the human endogenous retroviral protein. This human endogenous retroviral protein is herein generally referred to as HEMO. The application relates more particularly to shed forms of the HEMO protein, more particularly to those shed forms, which are released in the circulating blood. The application also relates to products deriving from the shed forms of HEMO, such as antibodies, nucleic acid vectors and engineered cells, as well as to the medical or biotechnological applications of these shed forms or derived products, notably in the fields of placental development, fetus protection, cancer treatment and stem cell production.

    NOX2 AS A BIOMARKER OF RADIOTHERAPY EFFICIENCY IN CANCER PATIENTS
    7.
    发明申请
    NOX2 AS A BIOMARKER OF RADIOTHERAPY EFFICIENCY IN CANCER PATIENTS 审中-公开
    NOX2作为癌症患者放射治疗效果的生物标志物

    公开(公告)号：WO2018050928A1

    公开(公告)日：2018-03-22

    申请号：PCT/EP2017/073677

    申请日：2017-09-19

    申请人： INSTITUT GUSTAVE-ROUSSY

    发明人： PERFETTINI, Jean-Luc ,  DEUTSCH, Eric ,  ALLOUCH, Awatef

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2800/52

    摘要： Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here the present inventors show that ionizing radiation induces the expression of interferon-regulatory factor 5 (IRF5) promoting thus macrophage activation toward a pro-inflammatory phenotype. They reveal that the activation of the Ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cis-platin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a proinflammatory phenotype. They further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. They also report that hypoxic conditions and the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, these results identify a novel signaling pathway involved in macrophage activation that may enhance effectiveness of radiotherapy through the re-programming of tumor infiltrating macrophages.

    摘要翻译： 虽然肿瘤相关巨噬细胞已广泛研究了放疗反应的控制，但涉及电离辐射介导的巨噬细胞活化的分子机制仍然难以捉摸。 在此，本发明人表明，电离辐射诱导干扰素调节因子5（IRF5）的表达，从而促进巨噬细胞活化为促炎症表型。 他们揭示，激活共济失调毛细血管扩张突变（ATM）激酶是电离辐射引起的巨噬细胞激活所必需的，而且在γ-干扰素，脂多糖或化学治疗剂（如顺铂）治疗后用于巨噬细胞重编程需要，强调 事实上激酶ATM在巨噬细胞表型转换为促炎症表型过程中起着核心作用。 他们进一步证明NADPH氧化酶2（NOX2）依赖性ROS产生在ATM激活的上游，并且在此过程中是必不可少的。 他们还报告说，缺氧条件和这种信号通路的任何成分（NOX2，ROS和ATM）的抑制都会损害巨噬细胞的促炎激活，并预测局部晚期直肠癌术前放疗的肿瘤反应差。 总之，这些结果确定了涉及巨噬细胞活化的新信号通路，其可通过重新编程肿瘤浸润巨噬细胞来提高放射疗法的有效性。

    PTPS-BASED VACCINES AGAINST CANCER
    8.
    发明申请
    PTPS-BASED VACCINES AGAINST CANCER 审中-公开
    基于PTPS的疫苗对抗癌症

    公开(公告)号：WO2017149118A1

    公开(公告)日：2017-09-08

    申请号：PCT/EP2017/055004

    申请日：2017-03-03

    申请人： INSTITUT GUSTAVE ROUSSY

    发明人： APCHER, Sébastien ,  FAHRAEUS, Robin ,  YAMAZAKI, Takahiro ,  PIERSON, Alison ,  BOULPICANTE, Mathilde

    IPC分类号： A61K39/00

    摘要： The present invention relates to the field of medicine. It more particularly relates to peptides, microvesicles containing such peptides, compositions containing same, in particular vaccine, and methods for stimulating an immune response in a subject.

    摘要翻译： 本发明涉及医学领域。 本发明更具体地涉及肽，包含此类肽的微泡，包含其的组合物，特别是疫苗，以及刺激受试者的免疫应答的方法。

    METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY
    9.
    发明申请
    METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY 审中-公开
    用于预测免疫疗法对象敏感性的方法和试剂盒

    公开(公告)号：WO2017140826A1

    公开(公告)日：2017-08-24

    申请号：PCT/EP2017/053577

    申请日：2017-02-17

    申请人： INSTITUT GUSTAVE ROUSSY

    发明人： ZITVOGEL, Laurence ,  JACQUELOT, Nicolas ,  ENOT, David ,  SEIJO-RUSAKIEWICZ, Sylvie

    IPC分类号： G01N33/574 ,  C07K16/30

    CPC分类号： G01N33/5743 ,  G01N33/57492 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2800/52

    摘要： The present invention relates to a method of predicting assessing or monitoring the sensitivity of a subject having a cancer to an immunotherapy, and to corresponding kits. The method of predicting, assessing or monitoring the sensitivity of a subject having a tumor to an immunotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one biomarker, for example at least two biomarkers, and when the expression level is determined a step b) of comparing said expression level to reference expression level(s) or to reference expression ratio(s), thereby predicting, assessing or monitoring whether the subject having a tumor is responsive or resistant to the proposed immunotherapy.

    摘要翻译： 本发明涉及一种预测评估或监测患有癌症的受试者对免疫疗法的敏感性的方法，以及相应的试剂盒。 预测，评估或监测具有肿瘤的受试者对免疫疗法的敏感性的方法通常包括步骤a）：在来自所述受试者的生物样品中测定至少一种生物标志物的存在，不存在或表达水平，用于 例如至少两种生物标志物，并且当表达水平被确定时，比较所述表达水平与参考表达水平或参考表达比率（s）的步骤b），由此预测，评估或监测患有肿瘤的受试者 对拟议的免疫治疗有反应或有抵抗力。

    A SCORING METHOD FOR PREDICTING THE EFFICIENCY OF A TREATMENT WITH ANTI-PD-1 AND/OR ANTI-PD-L1 MONOCLONAL ANTIBODIES
    10.
    发明申请
    A SCORING METHOD FOR PREDICTING THE EFFICIENCY OF A TREATMENT WITH ANTI-PD-1 AND/OR ANTI-PD-L1 MONOCLONAL ANTIBODIES 审中-公开
    用于预测抗PD-1和/或抗-PD-L1单克隆抗体治疗效率的评分方法

    公开(公告)号：WO2017050855A1

    公开(公告)日：2017-03-30

    申请号：PCT/EP2016/072477

    申请日：2016-09-21

    申请人： INSTITUT GUSTAVE ROUSSY

    发明人： GIRAULT, Isabelle ,  VAGNER, Stephan ,  ROBERT, Caroline ,  LANOY, Emilie ,  TEXIER, Matthieu ,  ADAM, Julien ,  SHEN, Shensi

    IPC分类号： G01N33/574 ,  G06F19/00

    CPC分类号： G01N33/574 ,  G01N2800/52 ,  G06F19/00 ,  G06F19/10 ,  G16H30/40 ,  G16H50/20 ,  G16H50/30

    摘要： The invention aims at a method implemented by computer means (CC) for assessing an efficiency of a cure of a cancer disease based on at least one antibody against protein PD-1 and/or its ligand PD-L1, wherein the method comprises the steps: - Obtaining data of at least one microscope (MIC) image (IM DAT) of cells of a tumor material (TAM) treated for performing a test to assess an interaction between protein PD-1 and its ligand PD-L1 in at least some of said cells, - Counting in said image a number of spots related to said interactions between PD-1 and PD-L1, and a number of nuclei in said image, and - Estimating a ratio between said number of spots and said number of nuclei with a view to assess an efficiency of a cure based on at least one antibody against protein PD-1 and/or its ligand PD-L1 on a cancer disease from which said tumor material results.

    摘要翻译： 本发明旨在通过计算机装置（CC）实施的方法，其基于至少一种针对蛋白质PD-1和/或其配体PD-L1的抗体来评估治愈癌症疾病的效率，其中该方法包括步骤 ： - 获得用于进行测试的至少一种显微镜（MIC）图像（IM DAT）的肿瘤材料（TAM）的细胞的数据，以评估至少一些蛋白质PD-1与其配体PD-L1之间的相互作用 - 在所述图像中计数与PD-1和PD-L1之间的所述相互作用相关的许多斑点以及所述图像中的多个核，以及 - 估计所述点数和所述核数之间的比率 以评估基于至少一种针对蛋白质PD-1和/或其配体PD-L1的抗体对所述肿瘤材料产生的癌症疾病的治疗效果。